Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year

Reuters03-14 22:15

Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year

Senseonics reported real-world evidence on the implantable Eversense 365 continuous glucose monitoring system, with results presented at the ATTD conference. The analysis covered 5,059 Eversense 365 sensors used by U.S. patients on open-loop insulin regimens and found an average transmitter wear time of 94%. Reported outcomes included a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66%. In a subgroup aged over 65 years, mean Time in Range was over 70% and average wear time was over 95%. Senseonics also reported early real-world data from about 120 people using Eversense 365 with the twiist automated insulin delivery system, showing a mean Time in Range of 77% and time in hypoglycemia of 3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603141015PRIMZONEFULLFEED9672153) on March 14, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619124849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-14 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619124849","market":"fut","top_or_hot":-1,"title":"Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Senseonics reported real-world evidence on the implantable Eversense 365 continuous glucose monitoring system, with results presented at the ATTD conference. The analysis covered 5,059 Eversense 365 sensors used by U.S. patients on open-loop insulin regimens and found an average transmitter wear time of 94%. Reported outcomes included a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66%. In a subgroup aged over 65 years, mean Time in Range was over 70% and average wear time was over 95%. Senseonics also reported early real-world data from about 120 people using Eversense 365 with the twiist automated insulin delivery system, showing a mean Time in Range of 77% and time in hypoglycemia of 3%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603141015PRIMZONEFULLFEED9672153) on March 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-14 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Senseonics reported real-world evidence on the implantable Eversense 365 continuous glucose monitoring system, with results presented at the ATTD conference. The analysis covered 5,059 Eversense 365 sensors used by U.S. patients on open-loop insulin regimens and found an average transmitter wear time of 94%. Reported outcomes included a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66%. In a subgroup aged over 65 years, mean Time in Range was over 70% and average wear time was over 95%. Senseonics also reported early real-world data from about 120 people using Eversense 365 with the twiist automated insulin delivery system, showing a mean Time in Range of 77% and time in hypoglycemia of 3%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603141015PRIMZONEFULLFEED9672153) on March 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260314:nNDL5nX5M8:1","article_id":"2619124849","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619124849","pubTimestamp":1773497737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Senseonics reported real-world evidence on the implantable Eversense 365 continuous glucose monitoring system, with results presented at the ATTD conference. The analysis covered 5,059 Eversense 365 sensors used by U.S. patients on open-loop insulin regimens and found an average transmitter wear time of 94%. Reported outcomes included a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66%. In a subgroup aged over 65 years, mean Time in Range was over 70% and average wear time was over 95%. Senseonics also reported early real-world data from about 120 people using Eversense 365 with the twiist automated insulin delivery system, showing a mean Time in Range of 77% and time in hypoglycemia of 3%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SENS":"Senseonics Holdings,Inc.","BK4082":"医疗保健设备","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Senseonics真实世界研究跟踪了5,059个Eversense 365传感器，一年内发射器磨损率为94%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":0.9,"NDAQ":0.9},"content_text":"Senseonics real-world study tracks 5,059 Eversense 365 sensors with 94% transmitter wear time over one year\n    \n\n        Senseonics reported real-world evidence on the implantable Eversense 365 continuous glucose monitoring system, with results presented at the ATTD conference. The analysis covered 5,059 Eversense 365 sensors used by U.S. patients on open-loop insulin regimens and found an average transmitter wear time of 94%. Reported outcomes included a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66%. In a subgroup aged over 65 years, mean Time in Range was over 70% and average wear time was over 95%. Senseonics also reported early real-world data from about 120 people using Eversense 365 with the twiist automated insulin delivery system, showing a mean Time in Range of 77% and time in hypoglycemia of 3%.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603141015PRIMZONEFULLFEED9672153) on March 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619124849","isCrawlerRequest":true}